Recent Research Funding

Faculty secure several million dollars annually for their research from various public and private sources, including the National Institutes of Health, U.S. Food and Drug Administration, National Multiple Sclerosis Society, foundations and pharmaceutical firms.

  • A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis, BEAT-MS (Protocol ITN077AI).Bianca Weinstock-Guttman (Principal Investigator). National Institute of Allergy & Infectious Diseases (NIAID), Division of Allergy, Immunology &Transplantation (DAIT) via a subaward. 1/1/2020-12/1/2026.
  • Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS) - Observational Participants.Bianca Weinstock-Guttman (Principal Investigator). PCORI. 1/1/2020-12/1/2025.
  • A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063).Bianca Weinstock-Guttman (Principal Investigator). Celgene International. 6/1/2020-12/1/2025.
  • Feasibility of the Multiple Sclerosis Performance Test for assessment of functional performance measures in patients with Multiple Sclerosis (US-MSG-18-11424).Bianca Weinstock-Guttman (Principal Investigator). Biogen. 6/1/2019-12/1/2024.
  • Network of Excellence in Neuroscience Clinical Trial: NeuroNEXT.Gil Wolfe (Principal Investigator). NIH/NINDS. $250,000. 7/1/2018-6/1/2023.
  • Neonatal Research Network.Osman Farooq (Co-Investigator), Michelle Hartley-McAndrew (Co-Investigator), Anne Marie Reynolds (Co-Principal Investigator). Eunice Kennedy Shriver National Institute of Child Health and Human Development. 4/1/2011-8/1/2022.
  • A study to evaluate the natural history of secondary progressive multiple sclerosis in never-treated or late starters compared to early treated patients.Bianca Weinstock-Guttman (Principal Investigator). Novartis. 3/1/2021-8/1/2022.
  • Evaluation of patient-reported outcomes associated with use of natalizumab in a real-world setting.Bianca Weinstock-Guttman (Co-Principal Investigator). Biogen. 9/1/2020-12/1/2021.
  • Evaluation of patient-reported outcomes associated with use of dimethyl fumarate in a real-world setting.Bianca Weinstock-Guttman (Principal Investigator). Biogen. 12/1/2019-12/1/2021.
  • A novel method for the investigation of the neural underpinnings of performance on the Symbol Digit Modalities Test in Multiple Sclerosis.Thomas Covey (Principal Investigator). National Multiple Sclerosis Society. $55,000. 10/1/2020-9/1/2021.
  • Supporting an aging workforce in future transportation and delivery work.Thomas Covey (Co-Principal Investigator). National Science Foundation. $149,580. 10/1/2020-9/1/2021.
  • A prospective study to validate the Expanded Timed Get Up and Go (ETGUG) in multiple sclerosis patients with varying levels of disability.Bianca Weinstock-Guttman (Principal Investigator). Biogen. 6/1/2018-8/1/2021.
  • The effects of working memory training on brain function, structure, and cognition in MS.Thomas Covey (Co-Principal Investigator). National Multiple Sclerosis Society. $622,839. 6/1/2017-6/1/2021.
  • Physiological mechanisms of a biomarker of recovery from concussion.Robert Zivadinov (Co-Investigator). National Institute of Health. 4/1/2016-4/1/2021.
  • The effects of Post-Traumatic Stress Disorder (PTSD) symptoms on behavioral, psychological, and neurophysiological measures of decision making in police officers.Thomas Covey (Co-Principal Investigator). National Institutes of Justice. $814,158. 1/1/2018-1/1/2021.
  • Grants and Sponsored Research(selected).Lawrence Wrabetz (Principal Investigator). 12/1/2007-12/1/2020.
  • Neurocognitive, electrophysiological and MRI changes associated with low level laser therapy (photobiomodulation) in the treatment of Traumatic Brain Injury: A pilot study.Thomas Covey (Co-Investigator). American Society for Laser Medicine and Surgery. $68,000. 10/1/2016-11/1/2020.
  • Delay discounting as a target for self-regulation in prediabetes.Robert Zivadinov (Co-Investigator). National Institute of Health. 10/1/2015-10/1/2020.
  • The effects of working memory training on brain function, structure, and cognition in MS.Ralph Benedict (Co-Investigator), Michael Dwyer, III (Co-Investigator), David Shucard (Co-Principal Investigator), Janet Shucard (Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator), Robert Zivadinov (Co-Investigator). National Multiple Sclerosis Society. $622,839. 6/1/2017-6/1/2020.
  • The effects of working memory training on brain function, structure, and cognition in MS.Ralph Benedict (Co-Investigator), Michael Dwyer, III (Co-Investigator), David Shucard (Co-Principal Investigator), Janet Shucard (Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator), Robert Zivadinov (Co-Investigator). National Multiple Sclerosis Society. $622,839. 6/1/2017-6/1/2020.